< 1 minute read
Dec. 20, 2021
M5717: the First Plasmodium eEF2 Inhibitor in The Clinic
M5717
oral plasmodium eEF2 inhibitor Ph. I candidate for malaria treatment from phenotypic screen & optimization The Lancet Merck Institute for Pharmacometrics
Loading...
